Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus

Journal of Cystic Fibrosis

Volumn 11, Issue 2, 2012, Pages 144-149

  Hillman, Magnus ^a   Eriksson, Leif ^a   Mared, Lena ^a   Helgesson, Karin ^b   Landin Olsson, Mona ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cystic fibrosis related diabetes (CFRD); Endocrinology; GLP 1; Intestinal hormones

Indexed keywords

C PEPTIDE; CARBOHYDRATE; FAT; GLUCAGON LIKE PEPTIDE 1; INSULIN; PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CARBOHYDRATE DIET; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DIET RESTRICTION; DISEASE COURSE; ENERGY; FEMALE; HUMAN; LIPID DIET; MALE; MEAL; PROTEIN BLOOD LEVEL; PROTEIN DIET;

ADULT; C-PEPTIDE; COMORBIDITY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; YOUNG ADULT;

EID: 84858286198     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.11.001     Document Type: Article

References (50)

1. Lannefors L., Lindgren A. Demographic transition of the Swedish cystic fibrosis community-results of modern care. Respir Med 2002 Sep, 96(9):681-685.
2. Lombardo F., De Luca F., Rosano M., Sferlazzas C., Lucanto C., Arrigo T., et al. Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia. Eur J Endocrinol 2003 Jul, 149(1):53-59.
3. de Valk H.W., van der Graaf E.A. Cystic fibrosis-related diabetes in adults: where can we go from here?. Rev Diabet Stud 2007, 4(1):6-12.
4. Moran A., Diem P., Klein D.J., Levitt M.D., Robertson R.P. Pancreatic endocrine function in cystic fibrosis. J Pediatr 1991 May, 118(5):715-723.
5. Iannucci A., Mukai K., Johnson D., Burke B. Endocrine pancreas in cystic fibrosis: an immunohistochemical study. Hum Pathol 1984 Mar, 15(3):278-284.
6. Moran A., Hardin D., Rodman D., Allen H.F., Beall R.J., Borowitz D., et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes research and clinical practice 1999, 61-73.
7. Minicucci L., Cotellessa M., Pittaluga L., Minuto N., d'Annunzio G., Avanzini M.A., et al. Beta-cell autoantibodies and diabetes mellitus family history in cystic fibrosis. J Pediatr Endocrinol Metab 2005 Aug, 18(8):755-760.
8. Stutchfield P.R., O'Halloran S.M., Smith C.S., Woodrow J.C., Bottazzo G.F., Heaf D. HLA type, islet cell antibodies, and glucose intolerance in cystic fibrosis. Arch Dis Child 1988 Oct, 63(10):1234-1239.
9. Ali B. Is cystic fibrosis-related diabetes an apoptotic consequence of ER stress in pancreatic cells?. Med Hypotheses 2009 Jan, 72(1):55-57.
10. Mohan K., Israel K.L., Miller H., Grainger R., Ledson M.J., Walshaw M.J. Long-term effect of insulin treatment in cystic fibrosis-related diabetes. Respiration 2008, 76(2):181-186.
11. Bizzarri C., Lucidi V., Ciampalini P., Bella S., Russo B., Cappa M. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Invest 2006 Mar, 29(3). RC1-4.
12. Rosenecker J., Eichler I., Bärmeier H., Hardt von der H. Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents. Pediatr Pulmonol 2001 Nov, 32(5):351-355.
13. Gutzwiller J.-P., Degen L., Heuss L., Beglinger C. Glucagon-like peptide 1 (GLP-1) and eating. Physiol Behav 2004 Aug, 82(1):17-19.
14. Gorrell M.D., Gysbers V., McCaughan G.W. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001 Sep, 54(3):249-264.
15. Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996 Jan, 81(1):327-332.
16. Schirra J., Katschinski M., Weidmann C., Schäfer T., Wank U., Arnold R., et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996 Jan. 1, 97(1):92-103.
17. Wettergren A., Wøjdemann M., Holst J.J. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998 Nov, 275(5 Pt 1):G984-G992.
18. Mojsov S., Weir G.C., Habener J.F. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987 Feb, 79(2):616-619.
19. Holst J.J., Orskov C., Nielsen O.V., Schwartz T.W. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987 Jan. 26, 211(2):169-174.
20. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003 Oct, 26(10):2929-2940.
21. Krentz A.J., Bailey C.J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005, 65(3):385-411.
22. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 Nov. 11, 368(9548):1696-1705.
23. Abbatecola A.M., Maggi S., Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging 2008, 25(11):913-925.
24. Mikhail N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2008 Jun, 17(6):845-853.
25. Bingley P.J., Bonifacio E., Mueller P.W. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003 May, 52(5):1128-1136.
26. Lanng S., Thorsteinsson B., Pociot F., Marshall M.O., Madsen H.O., Schwartz M., et al. Diabetes mellitus in cystic fibrosis: genetic and immunological markers. Acta Paediatr 1993 Feb, 82(2):150-154.
27. Kockum I., Lernmark A., Dahlquist G., Falorni A., Hagopian W.A., Landin-Olsson M., et al. Genetic and immunological findings in patients with newly diagnosed insulin-dependent diabetes mellitus. The Swedish Childhood Diabetes Study Group and The Diabetes Incidence in Sweden Study (DISS) Group. Horm Metab Res 1996 Jul, 28(7):344-347.
28. Kuo P., Stevens J.E., Russo A., Maddox A., Wishart J.M., Jones K.L., et al. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis-effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab 2011 May, 96(5):E851-E855.
29. Cucchiara S., Raia V., Minella R., Frezza T., De Vizia B., De Ritis G. Ultrasound measurement of gastric emptying time in patients with cystic fibrosis and effect of ranitidine on delayed gastric emptying. J Pediatr 1996 Apr, 128(4):485-488.
30. Collins C.E., Francis J.L., Thomas P., Henry R.L., O'Loughlin E.V. Gastric emptying time is faster in cystic fibrosis. J Pediatr Gastroenterol Nutr 1997 Nov, 25(5):492-498.
31. Bodet-Milin C., Querellou S., Oudoux A., Haloun A., Horeau-Llanglard D., Carlier T., et al. Delayed gastric emptying scintigraphy in cystic fibrosis patients before and after lung transplantation. J Heart Lung Transplant 2006 Sep, 25(9):1077-1083.
32. Tonelli A.R., Drane W.E., Collins D.P., Nichols W., Antony V.B., Olson E.L. Erythromycin improves gastric emptying half-time in adult cystic fibrosis patients with gastroparesis. J Cyst Fibros 2009 May, 8(3):193-197.
33. Dinjens W.N., Kate ten J., van der Linden E.P., Wijnen J.T., Khan P.M., Bosman F.T. Distribution of adenosine deaminase complexing protein (ADCP) in human tissues. J Histochem Cytochem 1989 Dec, 37(12):1869-1875.
34. Ohnuma K., Takahashi N., Yamochi T., Hosono O., Dang N.H., Morimoto C. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci 2008, 13:2299-2310.
35. Bauvois B., Sancéau J., Wietzerbin J. Human U937 cell surface peptidase activities: characterization and degradative effect on tumor necrosis factor-alpha. Eur J Immunol 1992 Apr, 22(4):923-930.
36. Laouar A., Villiers C., Sancéau J., Maison C., Colomb M., Wietzerbin J., et al. Inactivation of interleukin-6 in vitro by monoblastic U937 cell plasma membranes involves both protease and peptidyl-transferase activities. Eur J Biochem 1993 Aug. 1, 215(3):825-831.
37. Page M.J., Di Cera E. Serine peptidases: classification, structure and function. Cell Mol Life Sci 2008 Apr, 65(7-8):1220-1236.
38. Bauvois B., Djavaheri-Mergny M., Rouillard D., Dumont J., Wietzerbin J. Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells. Oncogene 2000 Jan. 13, 19(2):265-272.
39. Stefanovic V., Ardaillou N., Vlahovic P., Placier S., Ronco P., Ardaillou R. Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. Immunology 1993 Nov, 80(3):465-470.
40. Cordero O.J., Salgado F.J., Viñuela J.E., Nogueira M. Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiology 1997 Nov, 197(5):522-533.
41. Salgado F.J., Vela E., Martín M., Franco R., Nogueira M., Cordero O.J. Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes. Cytokine 2000 Jul, 12(7):1136-1141.
42. Sturm A., Hebestreit H., Koenig C., Walter U., Grossmann R. Platelet proinflammatory activity in clinically stable patients with CF starts in early childhood. J Cyst Fibros 2010 May, 9(3):179-186.
43. Mohan K., Miller H., Dyce P., Grainger R., Hughes R., Vora J., et al. Mechanisms of glucose intolerance in cystic fibrosis. Diabet Med 2009 Jun, 26(6):582-588.
44. Yung B., Noormohamed F.H., Kemp M., Hooper J., Lant A.F., Hodson M.E. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction. Diabet Med 2002 Mar, 19(3):221-226.
45. Hardin D.S., Ahn C., Rice J., Rice M., Rosenblatt R. Elevated gluconeogenesis and lack of suppression by insulin contribute to cystic fibrosis-related diabetes. J Investig Med 2008 Mar, 56(3):567-573.
46. Allen J.M., Penketh A.R., Adrian T.E., Lee Y.C., Sarson D.L., Hodson M.E., et al. Adult cystic fibrosis: postprandial response of gut regulatory peptides. Gastroenterology 1983 Dec, 85(6):1379-1383.
47. Lanng S., Thorsteinsson B., Røder M.E., Orskov C., Holst J.J., Nerup J., et al. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta Endocrinol 1993 Mar, 128(3):207-214.
48. Vilsbøll T., Toft-Nielsen M.B., Krarup T., Madsbad S., Dinesen B., Holst J.J. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 2000 Jun, 23(6):807-812.
49. Adrian T.E., McKiernan J., Johnstone D.I., Hiller E.J., Vyas H., Sarson D.L., et al. Hormonal abnormalities of the pancreas and gut in cystic fibrosis. Gastroenterology 1980 Sep, 79(3):460-465.
50. Murphy M.S., Brunetto A.L., Pearson A.D., Ghatei M.A., Nelson R., Eastham E.J., et al. Gut hormones and gastrointestinal motility in children with cystic fibrosis. Dig Dis Sci 1992 Feb, 37(2):187-192.